Symbols / NTRB
NTRB Chart
About
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 51.99M |
| Enterprise Value | 48.80M | Income | -34.59M | Sales | 2.28M |
| Book/sh | 0.62 | Cash/sh | 0.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -18.57 | PEG | — |
| P/S | 22.82 | P/B | 6.88 | P/C | — |
| EV/EBITDA | -5.40 | EV/Sales | 21.42 | Quick Ratio | 7.07 |
| Current Ratio | 7.53 | Debt/Eq | 3.42 | LT Debt/Eq | — |
| EPS (ttm) | -3.05 | EPS next Y | -0.23 | EPS Growth | — |
| Revenue Growth | -46.40% | Earnings | 2025-12-11 06:00 | ROA | -55.22% |
| ROE | -136.08% | ROIC | — | Gross Margin | 33.50% |
| Oper. Margin | -11.21% | Profit Margin | 0.00% | Shs Outstand | 12.17M |
| Shs Float | 4.91M | Short Float | 3.87% | Short Ratio | 7.84 |
| Short Interest | — | 52W High | 11.68 | 52W Low | 3.96 |
| Beta | 1.78 | Avg Volume | 32.79K | Volume | 5.39K |
| Target Price | $15.00 | Recom | None | Prev Close | $4.42 |
| Price | $4.27 | Change | -3.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$4.27
Latest analyst target
3. DCF / Fair value
$-3.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.27
Low
$15.00
High
$15.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-01-22 | init | Noble Capital Markets | — → Outperform | $13 |
| 2022-07-26 | main | Small Cap Consumer Research | — → Buy | $21 |
- The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable - Yahoo Finance hu, 29 Jan 2026 08
- [424B3] NutriBand Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan hu, 12 Feb 2026 08
- Nutriband (NASDAQ:NTRB) shareholders are up 27% this past week, but still in the red over the last five years - simplywall.st ue, 30 Dec 2025 08
- Nutriband stock jumps after FDA meeting for abuse-deterrent fentanyl patch - Investing.com ue, 28 Oct 2025 07
- Nutriband Stock Jumps 17% After Agreement To Sell 90% Of Pocono Pharma For $5 Mln - Nasdaq Mon, 29 Dec 2025 08
- NutriBand Inc. SEC 10-Q Report - TradingView hu, 11 Dec 2025 08
- Nutriband Inc. Declares 25% Preferred Stock Dividend to Shareholders - Quiver Quantitative Wed, 02 Jul 2025 07
- Price-Driven Insight from (NTRB) for Rule-Based Strategy - Stock Traders Daily Mon, 15 Dec 2025 08
- Nutriband shareholders approve proposals and expand board leadership - TipRanks ue, 03 Feb 2026 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 19
- Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval - Yahoo Finance Wed, 02 Jul 2025 07
- Sale of Pocono Pharma funds development of abuse-deterrent fentanyl patch - Stock Titan Mon, 29 Dec 2025 08
- After-Hours Rally Lifts PALI, HCTI, NTRB, KPTI, EDIT, And CGON On Mixed News And Strategic Moves - Nasdaq Fri, 10 Oct 2025 07
- Nutriband Inc. Sells 90% Stake in Pocono Pharmaceutical to Earthvision Bio for $5 Million - Quiver Quantitative Mon, 29 Dec 2025 08
- Nutriband First Quarter 2026 Earnings: EPS Beats Expectations - simplywall.st Mon, 02 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.21M | -4.57M | -3.82M | -3.61M |
| TotalUnusualItems | -3.96M | -554.42K | -327.33K | -2.13M |
| TotalUnusualItemsExcludingGoodwill | -3.96M | -554.42K | -327.33K | -2.13M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.48M | -5.49M | -4.48M | -6.18M |
| ReconciledDepreciation | 285.05K | 287.72K | 330.14K | 318.26K |
| ReconciledCostOfRevenue | 1.40M | 1.22M | 1.33M | 917.84K |
| EBITDA | -10.18M | -5.12M | -4.15M | -5.74M |
| EBIT | -10.46M | -5.41M | -4.48M | -6.06M |
| NetInterestIncome | 170.26K | -58.97K | -8.29K | -118.42K |
| InterestExpense | 21.41K | 75.81K | 8.29K | 118.42K |
| InterestIncome | 191.67K | 16.85K | 0.00 | |
| NormalizedIncome | -6.52M | -4.93M | -4.16M | -4.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.48M | -5.49M | -4.48M | -6.18M |
| TotalExpenses | 8.83M | 6.96M | 6.23M | 5.35M |
| TotalOperatingIncomeAsReported | -10.28M | -4.87M | -4.48M | -6.11M |
| DilutedAverageShares | 10.61M | 7.95M | 8.46M | 7.93M |
| BasicAverageShares | 10.61M | 7.95M | 8.46M | 7.93M |
| DilutedEPS | -0.99 | -0.69 | -0.53 | -0.80 |
| BasicEPS | -0.99 | -0.69 | -0.53 | -0.80 |
| DilutedNIAvailtoComStockholders | -10.48M | -5.49M | -4.48M | -6.37M |
| NetIncomeCommonStockholders | -10.48M | -5.49M | -4.48M | -6.37M |
| OtherunderPreferredStockDividend | 0.00 | 196.59K | ||
| NetIncome | -10.48M | -5.49M | -4.48M | -6.18M |
| NetIncomeIncludingNoncontrollingInterests | -10.48M | -5.49M | -4.48M | -6.18M |
| NetIncomeContinuousOperations | -10.48M | -5.49M | -4.48M | -6.18M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -10.48M | -5.49M | -4.48M | -6.18M |
| OtherIncomeExpense | -3.96M | -554.42K | -327.33K | -2.13M |
| SpecialIncomeCharges | -3.96M | -554.42K | -327.33K | -2.13M |
| OtherSpecialCharges | 368.04K | 554.42K | -53.03K | |
| ImpairmentOfCapitalAssets | 3.60M | 0.00 | 327.33K | 2.18M |
| NetNonOperatingInterestIncomeExpense | 170.26K | -58.97K | -8.29K | -118.42K |
| InterestExpenseNonOperating | 21.41K | 75.81K | 8.29K | 118.42K |
| InterestIncomeNonOperating | 191.67K | 16.85K | 0.00 | |
| OperatingIncome | -6.69M | -4.87M | -4.15M | -3.93M |
| OperatingExpense | 7.43M | 5.73M | 4.90M | 4.43M |
| ResearchAndDevelopment | 3.12M | 1.96M | 982.23K | 411.38K |
| SellingGeneralAndAdministration | 4.31M | 3.77M | 3.92M | 4.02M |
| GeneralAndAdministrativeExpense | 4.02M | |||
| OtherGandA | 4.02M | |||
| GrossProfit | 743.32K | 862.11K | 750.41K | 504.31K |
| CostOfRevenue | 1.40M | 1.22M | 1.33M | 917.84K |
| TotalRevenue | 2.14M | 2.09M | 2.08M | 1.42M |
| OperatingRevenue | 2.14M | 2.09M | 2.08M | 1.42M |
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 32.40K | 10.00K | 10.00K | 32.81K |
| OrdinarySharesNumber | 11.07M | 8.86M | 7.83M | 9.15M |
| ShareIssued | 11.11M | 8.87M | 7.84M | 9.18M |
| TotalDebt | 186.35K | 241.28K | 185.81K | 134.57K |
| TangibleBookValue | 4.45M | 749.24K | 2.77M | 5.58M |
| InvestedCapital | 6.62M | 6.65M | 8.69M | 11.97M |
| WorkingCapital | 3.81M | 22.77K | 1.95M | 4.69M |
| NetTangibleAssets | 4.45M | 749.24K | 2.77M | 5.58M |
| CapitalLeaseObligations | 0.00 | 34.28K | 65.57K | 19.33K |
| CommonStockEquity | 6.43M | 6.44M | 8.57M | 11.86M |
| TotalCapitalization | 6.49M | 6.52M | 8.67M | 11.96M |
| TotalEquityGrossMinorityInterest | 6.43M | 6.44M | 8.57M | 11.86M |
| StockholdersEquity | 6.43M | 6.44M | 8.57M | 11.86M |
| GainsLossesNotAffectingRetainedEarnings | -304.00 | -304.00 | -304.00 | -304.00 |
| OtherEquityAdjustments | -304.00 | -304.00 | -304.00 | -304.00 |
| TreasuryStock | 148.55K | 32.64K | 32.64K | 104.47K |
| RetainedEarnings | -38.46M | -27.98M | -22.49M | -18.01M |
| AdditionalPaidInCapital | 45.03M | 34.44M | 31.09M | 29.97M |
| CapitalStock | 11.07K | 8.86K | 7.83K | 9.15K |
| CommonStock | 11.07K | 8.86K | 7.83K | 9.15K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.04M | 1.08M | 883.39K | 880.38K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 58.20K | 79.83K | 134.77K | 101.12K |
| LongTermDebtAndCapitalLeaseObligation | 58.20K | 79.83K | 134.77K | 101.12K |
| LongTermCapitalLeaseObligation | 0.00 | 34.28K | 0.00 | |
| LongTermDebt | 58.20K | 79.83K | 100.50K | 101.12K |
| CurrentLiabilities | 982.85K | 999.09K | 748.61K | 779.26K |
| CurrentDeferredLiabilities | 155.88K | 157.50K | 162.90K | 106.27K |
| CurrentDeferredRevenue | 155.88K | 157.50K | 162.90K | 106.27K |
| CurrentDebtAndCapitalLeaseObligation | 128.14K | 161.46K | 51.03K | 33.45K |
| CurrentCapitalLeaseObligation | 0.00 | 34.28K | 31.29K | 19.33K |
| CurrentDebt | 128.14K | 127.18K | 19.74K | 14.12K |
| OtherCurrentBorrowings | 128.14K | 127.18K | 19.74K | 14.12K |
| CurrentNotesPayable | 0.00 | 0.00 | 0.00 | |
| PayablesAndAccruedExpenses | 698.82K | 680.13K | 534.68K | 639.54K |
| TotalAssets | 7.47M | 7.52M | 9.46M | 12.74M |
| TotalNonCurrentAssets | 2.68M | 6.50M | 6.76M | 7.27M |
| GoodwillAndOtherIntangibleAssets | 1.98M | 5.69M | 5.80M | 6.28M |
| OtherIntangibleAssets | 261.39K | 667.28K | 780.43K | 926.91K |
| Goodwill | 1.72M | 5.02M | 5.02M | 5.35M |
| NetPPE | 695.06K | 806.30K | 960.49K | 998.34K |
| AccumulatedDepreciation | -853.60K | -681.69K | -507.12K | -323.46K |
| GrossPPE | 1.55M | 1.49M | 1.47M | 1.32M |
| OtherProperties | 144.59K | 175.96K | 207.34K | 163.63K |
| MachineryFurnitureEquipment | 1.40M | 1.31M | 1.26M | 1.16M |
| CurrentAssets | 4.79M | 1.02M | 2.69M | 5.47M |
| PrepaidAssets | 196.66K | 211.67K | 365.93K | 370.47K |
| Inventory | 212.04K | 168.60K | 229.34K | 131.65K |
| FinishedGoods | 16.61K | 8.71K | ||
| WorkInProcess | 46.26K | 7.47K | ||
| RawMaterials | 149.18K | 152.43K | ||
| Receivables | 73.85K | 148.65K | 113.05K | 71.38K |
| AccountsReceivable | 73.85K | 148.65K | 113.05K | 71.38K |
| CashCashEquivalentsAndShortTermInvestments | 4.31M | 492.94K | 1.99M | 4.89M |
| CashAndCashEquivalents | 4.31M | 492.94K | 1.99M | 4.89M |
| Line Item | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.72M | -3.58M | -3.07M | -2.89M |
| RepurchaseOfCapitalStock | -148.55K | 0.00 | -119.01K | -104.47K |
| RepaymentOfDebt | -20.66K | -19.76K | -17.80K | -1.63M |
| IssuanceOfDebt | 300.00K | 2.11M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 8.41M | 0.00 | 0.00 | 6.42M |
| CapitalExpenditure | -92.04K | -51.76K | -79.30K | -81.59K |
| InterestPaidSupplementalData | 5.63K | 7.35K | 4.27K | 18.60K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 4.31M | 492.94K | 1.99M | 4.89M |
| BeginningCashPosition | 492.94K | 1.99M | 4.89M | 151.99K |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | ||
| ChangesInCash | 3.82M | -1.49M | -2.91M | 4.74M |
| FinancingCashFlow | 8.54M | 2.09M | 160.07K | 7.63M |
| CashFlowFromContinuingFinancingActivities | 8.54M | 2.09M | 160.07K | 7.63M |
| ProceedsFromStockOptionExercised | 0.00 | 296.88K | 2.94M | |
| NetCommonStockIssuance | 8.26M | 0.00 | -119.01K | 6.31M |
| CommonStockPayments | -148.55K | 0.00 | -119.01K | -104.47K |
| CommonStockIssuance | 8.41M | 0.00 | 0.00 | 6.42M |
| NetIssuancePaymentsOfDebt | 279.34K | 2.09M | -17.80K | -1.63M |
| NetLongTermDebtIssuance | 279.34K | 2.09M | -17.80K | -1.63M |
| LongTermDebtPayments | -20.66K | -19.76K | -17.80K | -1.63M |
| LongTermDebtIssuance | 300.00K | 2.11M | 0.00 | 0.00 |
| InvestingCashFlow | -92.04K | -51.76K | -79.30K | -81.59K |
| CashFlowFromContinuingInvestingActivities | -92.04K | -51.76K | -79.30K | -81.59K |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -92.04K | -51.76K | -79.30K | -81.59K |
| PurchaseOfPPE | -92.04K | -51.76K | -79.30K | -81.59K |
| OperatingCashFlow | -4.63M | -3.53M | -2.99M | -2.81M |
| CashFlowFromContinuingOperatingActivities | -4.63M | -3.53M | -2.99M | -2.81M |
| ChangeInWorkingCapital | 34.09K | 223.22K | -219.32K | -541.38K |
| ChangeInOtherWorkingCapital | -1.62K | -5.40K | 56.64K | 19.42K |
| ChangeInOtherCurrentLiabilities | -34.28K | -31.29K | -36.29K | -9.23K |
| ChangeInPayablesAndAccruedExpense | 23.61K | 198.89K | -104.86K | -145.26K |
| ChangeInPrepaidAssets | 15.01K | 154.26K | 4.55K | -370.47K |
| ChangeInInventory | -43.44K | 60.73K | -97.69K | -78.80K |
| ChangeInReceivables | 74.80K | -153.97K | -41.66K | 42.97K |
| ChangesInAccountReceivables | 74.80K | -153.97K | -41.66K | 42.97K |
| OtherNonCashItems | 31.37K | 31.38K | 151.97K | 564.38K |
| StockBasedCompensation | 1.54M | 742.70K | 732.13K | 897.83K |
| ProvisionandWriteOffofAssets | 0.00 | 118.36K | 0.00 | |
| AssetImpairmentCharge | 3.60M | 0.00 | 327.33K | 2.18M |
| DepreciationAmortizationDepletion | 285.05K | 287.72K | 330.14K | 318.26K |
| DepreciationAndAmortization | 285.05K | 287.72K | 330.14K | 318.26K |
| AmortizationCashFlow | 113.15K | 113.15K | 146.48K | |
| AmortizationOfIntangibles | 113.15K | 113.15K | 146.48K | |
| Depreciation | 171.90K | 174.57K | 183.66K | 318.26K |
| OperatingGainsLosses | 368.04K | 554.42K | 174.03K | -53.03K |
| GainLossOnInvestmentSecurities | 174.03K | |||
| NetIncomeFromContinuingOperations | -10.48M | -5.49M | -4.48M | -6.18M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NTRB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|